Liu et al. found that SNS/β-adrenergic receptors (β-ARs)/CCL2 stimulate the peripheral SNS and β-ARs signaling in tumor cells and tumor-infiltrated myeloid cells, which results in the inhibition of CCL2 production and the activation of anti-tumor immunity. This evidence concerns the gene CCL2 and neoplasm.